Black Rock Inc. Entrada Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,486,168 shares of TRDA stock, worth $20.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,486,168

Previous 1,502,537 1.09%

Holding current value

$20.8 Million

Previous $22.7 Million 7.12%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$11.58 - $17.0 $189,553 - $278,273	-16,369 Reduced 1.09%	1,486,168 $21.1 Million
Q4 2023 Feb 13, 2024	BUY	$11.36 - $16.99 $1.11 Million - $1.67 Million	98,134 Added 6.99%	1,502,537 $22.7 Million
Q3 2023 Nov 13, 2023	SELL	$13.61 - $18.01 $19,094 - $25,268	-1,403 Reduced 0.1%	1,404,403 $22.2 Million
Q2 2023 Aug 11, 2023	BUY	$11.02 - $18.01 $13.2 Million - $21.5 Million	1,193,821 Added 563.16%	1,405,806 $21.3 Million
Q1 2023 May 12, 2023	BUY	$9.58 - $16.2 $229,833 - $388,654	23,991 Added 12.76%	211,985 $3.07 Million

Q4 2022 Feb 13, 2023	BUY	$13.52 - $22.89 $546,221 - $924,778	40,401 Added 27.37%	187,994 $2.54 Million
Q3 2022 Nov 14, 2022	BUY	$9.65 - $15.76 $797,032 - $1.3 Million	82,594 Added 127.07%	147,593 $2.33 Million
Q2 2022 Aug 12, 2022	SELL	$5.49 - $12.94 $2.09 Million - $4.92 Million	-380,521 Reduced 85.41%	64,999 $791,000
Q1 2022 May 12, 2022	BUY	$7.99 - $16.93 $8,741 - $18,521	1,094 Added 0.25%	445,520 $4.18 Million
Q4 2021 Feb 10, 2022	BUY	$13.7 - $35.0 $6.09 Million - $15.6 Million	444,426 New	444,426 $7.61 Million

Others Institutions Holding TRDA

# of Institutions

Shares Held

25.7M

Call Options Held

Put Options Held

View Full List

About Entrada Therapeutics, Inc.

Ticker TRDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,368,500
Market Cap $439M
Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...

More about TRDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account